)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
China Traditional Chinese Medicine
China Traditional Chinese Medicine (570) investor relations material
China Traditional Chinese Medicine H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary28 Aug, 2026
Executive summary
Revenue for H1 2026 was RMB5,438.5 million, down 27.1% year-over-year, mainly due to policy-driven declines and weaker demand in concentrated TCM granules.
Gross profit fell 29.0% to RMB2,580.8 million, with gross margin decreasing by 1.2 percentage points to 47.5%.
Net loss widened to RMB834.7 million from RMB141.8 million in H1 2025, driven by lower sales, goodwill impairment, and increased asset impairments; net profit margin at -15.3%.
Basic and diluted loss per share was RMB-15.42 cents, compared to RMB-2.14 cents in the prior year period.
Financial highlights
Revenue by segment: Concentrated TCM granules RMB1,932.9m (-35.4%), TCM finished drugs RMB1,663.0m (-28.0%), TCM decoction pieces RMB1,559.6m (-2.3%), Chinese medicinal herbs/integration RMB189.6m (-57.5%), TCM great health RMB93.4m (-23.5%).
Gross profit margin: 47.5% (down 1.2pp); net profit margin: -15.3% (down 13.4pp).
Goodwill impairment of RMB645.2m recognized, mainly in the concentrated TCM granules business.
Selling and distribution expenses decreased 26.1% to RMB1,890.1m; administrative expenses rose 10.3% to RMB552.1m.
R&D expenses dropped 26.8% to RMB187.5m; finance costs decreased to RMB33.9m.
Outlook and guidance
The company plans to deepen reform, focus on quality improvement, and drive innovation-led growth in H2 2026.
Strategic priorities include expanding market share in TCM decoction pieces, adapting to policy reforms in granules, and strengthening academic promotion for finished drugs.
Emphasis on digital transformation, operational efficiency, and compliance to support long-term stability.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from China Traditional Chinese Medicine
- Revenue declined 10.7% and net loss reached RMB458.1 million amid restructuring and impairments.570
H2 2025 - Revenue fell 11% and a net loss of RMB141.8 million was recorded amid market headwinds.570H1 2025
- Revenue and profit dropped sharply, but TCM finished drugs and decoction pieces grew.570H1 2024
- Net profit dropped 98.5% on lower revenue and asset impairments, despite resilient core segments.570H2 2024
Next China Traditional Chinese Medicine earnings date
H2 202623 Mar, 2027
China Traditional Chinese Medicine
Next China Traditional Chinese Medicine earnings date
H2 202623 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
China Traditional Chinese Medicine Holdings Co. Limited is engaged in the research, production, and distribution of traditional Chinese medicines. The company focuses on manufacturing a wide range of herbal medicines and health products, leveraging traditional Chinese medicinal practices combined with modern pharmaceutical technologies. Its product portfolio spans various therapeutic areas, providing treatments for respiratory, cardiovascular, gastrointestinal, and orthopedic health, among others. China Traditional Chinese Medicine Holdings operates through its network of production facilities, retail pharmacies, and distribution channels, serving markets primarily in China and select international regions. The company is headquartered in Foshan, China, and its shares are listed on the HKEX.